Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology
September 23, 2021 - LAUSANNE, Switzerland and FRAMINGHAM, Mass —(BUSINESS WIRE)— Galderma, the world’s largest independent dermatology company, and Sofregen Medical, Inc., a medical device company pioneering the use of silk protein for tissue building and regeneration, announced today they have signed a co-development and option-to-acquire agreement. This collaboration will further expand …
PENTAX Medical Enters Into An Exclusive Distribution Agreement With Sofregen For Novel Silk Voice Injectable
MONTVALE, N.J., Oct. 28, 2020 /PRNewswire/ -- PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy solutions, announced today a distribution agreement with Sofregen Medical Inc. for its Silk Voice Injectable Implant. Under the terms of the agreement, PENTAX Medical will serve as the exclusive …
Soft Tissue Engineering Biotechnology Company Sofregen Raises $8 Million in Series B Funding Round
BOSTON, Dec. 17, 2019 /PRNewswire/ — Sofregen Medical, Inc. (Sofregen), an early stage medical device company, announced today that it has raised $8 million in new funding. The company is developing an advanced platform of products based on silk protein – also known as fibroin – that has been shown to have unique properties for …
Sofregen Receives 510(k) Clearance for Silk Voice® - The First and Only Natural Silk Protein Injectable Product for Tissue Bulking
MEDFORD, Mass. Sofregen Medical, Inc. (Sofregen), an early stage commercial biotechnology company developing products for medical aesthetics and reconstructive surgery, announced today that Silk Voice has been cleared by the U.S. Food and Drug Administration (FDA) for augmenting vocal fold tissue for phonation improvement. This is the first and only FDA cleared product …
